公开(公告)号：US08779148B2

公开(公告)日：2014-07-15

申请号：US14068956

申请日：2013-10-31

Applicant: Pfizer Inc.

Inventor： Usa Reilly ,  Michael Joseph Melnick ,  Matthew Frank Brown ,  Mark Stephen Plummer ,  Justin Ian Montgomery ,  Ye Che ,  Loren Michael Price

IPC: A61K31/44 ,  C07D211/72 ,  C07D413/10 ,  C07D417/12 ,  C07D213/64 ,  C07D405/12 ,  C07D213/69 ,  C07D405/04 ,  C07D401/04 ,  C07D401/10

CPC classification number: C07D405/04 ,  C07D213/64 ,  C07D213/69 ,  C07D401/04 ,  C07D401/10 ,  C07D405/12 ,  C07D413/10 ,  C07D417/12

Abstract: The present invention is directed to a new class of hydroxamic acid derivatives, their use as LpxC inhibitors and, more specifically, their use to treat bacterial infections.

公开(公告)号：US11981696B2

公开(公告)日：2024-05-14

申请号：US16980616

申请日：2019-03-14

Applicant: Pfizer Inc.

Inventor： Tamim Fehme Braish ,  Matthew Frank Brown ,  Ye Che ,  Richard Andrew Ewin ,  Timothy Allan Johnson ,  Michael Joseph Melnick ,  Justin Ian Montgomery ,  Mark Stephen Plummer ,  Loren Michael Price ,  Usa Reilly ,  Daniel Uccello

IPC: C07F9/58 ,  A61P31/04 ,  C07F5/02

CPC classification number: C07F9/58 ,  A61P31/04 ,  C07F5/022

Abstract: The present invention is directed to a new fluoro-pyridinone hydroxamic acid phosphates and boronates of Formulae I, II and III




wherein Q is selected from the group consisting of —P(O)(OH)2, —P(O)(OH)(O−M+), —P(O)(O−M+)2 and —P(O)(O−)2M2+; M+ at each occurrence is a pharmaceutically acceptable monovalent cation; and M2+ is a pharmaceutically acceptable divalent cation and their use as LpxC inhibitors and, more specifically, their use to treat bacterial infections.

公开(公告)号：US20210017205A1

公开(公告)日：2021-01-21

申请号：US16980616

申请日：2019-03-14

Applicant: Pfizer Inc.

Inventor： Tamim Fehme Braish ,  Matthew Frank Brown ,  Ye Che ,  Richard Andrew Ewin ,  Timothy Allan Johnson ,  Michael Joseph Melnick ,  Justin Ian Montgomery ,  Mark Stephen Plummer ,  Loren Michael Price ,  Usa Reilly ,  Daniel Uccello

IPC: C07F9/58 ,  C07F5/02 ,  A61P31/04

Abstract: The present invention is directed to a new fluoro-pyridinone hydroxamic acid phosphates and boronates of Formulae I, II and III wherein Q is selected from the group consisting of —P(O)(OH)2, —P(O)(OH)(O−M+), —P(O)(O−M+)2 and —P(O)(O−)2M2+; M+ at each occurrence is a pharmaceutically acceptable monovalent cation; and M2+ is a pharmaceutically acceptable divalent cation and their use as LpxC inhibitors and, more specifically, their use to treat bacterial infections.

公开(公告)号：US20140057919A1

公开(公告)日：2014-02-27

申请号：US14068956

申请日：2013-10-31

Applicant: Pfizer Inc.

Inventor： Usa Reilly ,  Michael Joseph Melnick ,  Matthew Frank Brown ,  Mark Stephen Plummer ,  Justin Ian Montgomery ,  Ye Che ,  Loren Michael Price

IPC: C07D405/04 ,  C07D213/64 ,  C07D401/04 ,  C07D401/10

CPC classification number: C07D405/04 ,  C07D213/64 ,  C07D213/69 ,  C07D401/04 ,  C07D401/10 ,  C07D405/12 ,  C07D413/10 ,  C07D417/12

Abstract: The present invention is directed to a new class of hydroxamic acid derivatives, their use as LpxC inhibitors and, more specifically, their use to treat bacterial infections.

Abstract translation: 本发明涉及一类新的异羟肟酸衍生物，它们用作LpxC抑制剂，更具体地，其用于治疗细菌感染。